The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Lung Cancer
Open accessAbstract
The Molecular Origins of Cancer series continues with this review of molecular and genetic mechanisms of lung cancer. The authors review genetic susceptibility to lung cancer and four genes of importance in the evolution of the disease: EGFR, KRAS, the PI3K–Akt–mTOR complex, and TITF1. They also discuss gene profiling and protein profiling, with emphasis on the clinical value of these methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
RetractedA Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
Potti, A., Mukherjee, S., Petersen, R., Dressman, H. K., Bild, A., Koontz, J., Kratzke, R., Watson, M. A., Kelley, M., Ginsburg, G. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060467 · Cited by 576
RetractedLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Self-citationMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Lung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Guo, X., Zhang, Y., Zheng, L., Zheng, C., Song, J., Zhang, Q., Kang, B., Liu, Z., Jin, L., Xing, R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0045-3 · Cited by 1,651
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Alveolar progenitor and stem cells in lung development, renewal and cancer
Desai, T. J., Brownfield, D. G., & Krasnow, M. A. (2014) · Nature · doi:10.1038/nature12930 · Cited by 1,060
Alberg, A. J., & Samet, J. M. (2010) · Murray and Nadel's Textbook of Respiratory Medicine · doi:10.1016/b978-1-4160-4710-0.00046-8 · Cited by 1,060
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Self-citationVolatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways
Hakim, M., Broza, Y. Y., Barash, O., Peled, N., Phillips, M., Amann, A., & Haick, H. (2012) · Chemical Reviews · doi:10.1021/cr300174a · Cited by 953
Progress and prospects of early detection in lung cancer
Blandin Knight, S., Crosbie, P. A., Balata, H., Chudziak, J., Hussell, T., & Dive, C. (2017) · Open Biology · doi:10.1098/rsob.170070 · Cited by 935
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 894
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Self-citationOkayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1403 · Cited by 874
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer
Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O’Brien, J. P., Pierce, K. A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.007 · Cited by 737
Alberg, A. J., Brock, M. V., & Samet, J. M. (2016) · Murray and Nadel's Textbook of Respiratory Medicine · doi:10.1016/b978-1-4557-3383-5.00052-x · Cited by 781
The epidemiology of lung cancer
de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.05.06 · Cited by 716
Assessment, origin, and implementation of breath volatile cancer markers
Haick, H., Broza, Y. Y., Mochalski, P., Ruzsanyi, V., & Amann, A. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60329f · Cited by 644
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610
The transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Cohen, J. D., Javed, A. A., Thoburn, C., Wong, F., Tie, J., Gibbs, P., Schmidt, C. M., Yip-Schneider, M. T., Allen, P. J., Schattner, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704961114 · Cited by 582
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 517
TGF-β Signaling in Lung Health and Disease
Saito, A., Horie, M., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082460 · Cited by 490
The mutation spectrum revealed by paired genome sequences from a lung cancer patient
Lee, W., Jiang, Z., Liu, J., Haverty, P. M., Guan, Y., Stinson, J., Yue, P., Zhang, Y., Pant, K. P., Bhatt, D., et al. (2010) · Nature · doi:10.1038/nature09004 · Cited by 490
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Chansky, K., Sculier, J.-P., Crowley, J. J., Giroux, D., Van Meerbeeck, J., & Goldstraw, P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a7716e · Cited by 456
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Ruiz-Cordero, R., & Devine, W. P. (2020) · Surgical Pathology Clinics · doi:10.1016/j.path.2019.11.002 · Cited by 448
Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent Inflammation
Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H., & Karin, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.008 · Cited by 438
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Hedgehog beyond medulloblastoma and basal cell carcinoma
Teglund, S., & Toftgård, R. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.003 · Cited by 426
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., & Quintás-Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 418
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Jafri, S. H., Shi, R., & Mills, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-158 · Cited by 389
Alterations of the Notch pathway in lung cancer
Westhoff, B., Colaluca, I. N., D'Ario, G., Donzelli, M., Tosoni, D., Volorio, S., Pelosi, G., Spaggiari, L., Mazzarol, G., Viale, G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907781106 · Cited by 387
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer
Gallardo, E., Navarro, A., Viñolas, N., Marrades, R. M., Diaz, T., Gel, B., Quera, A., Bandres, E., Garcia-Foncillas, J., Ramirez, J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp219 · Cited by 342
Camidge, D. R., Kono, S. A., Flacco, A., Tan, A.-C., Doebele, R. C., Zhou, Q., Crino, L., Franklin, W. A., & Varella-Garcia, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0851 · Cited by 341
Kratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z.-H., Gao, W., Pham, P. T., Mulvihill, M. S., Ziaei, F., Zhang, H., Su, B., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61941-7 · Cited by 333
Lung Cancer Epidemiology, Risk Factors, and Prevention
de Groot, P., & Munden, R. F. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.006 · Cited by 332
Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer
Hanash, S. M., Baik, C. S., & Kallioniemi, O. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.220 · Cited by 328
T helper 17 cells play a critical pathogenic role in lung cancer
Chang, S. H., Mirabolfathinejad, S. G., Katta, H., Cumpian, A. M., Gong, L., Caetano, M. S., Moghaddam, S. J., & Dong, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319051111 · Cited by 326
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Dotto, G. P., & Rustgi, A. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.004 · Cited by 319
Inorganic nanoparticles for biomedicine: where materials scientists meet medical research
Giner-Casares, J. J., Henriksen-Lacey, M., Coronado-Puchau, M., & Liz-Marzán, L. M. (2016) · Materials Today · doi:10.1016/j.mattod.2015.07.004 · Cited by 317
Shi, X., Sun, M., Liu, H., Yao, Y., Kong, R., Chen, F., & Song, Y. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22120 · Cited by 300
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 300
Wilkerson, M. D., Yin, X., Walter, V., Zhao, N., Cabanski, C. R., Hayward, M. C., Miller, C. R., Socinski, M. A., Parsons, A. M., Thorne, L. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036530 · Cited by 298
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Paul, M. K., Bisht, B., Darmawan, D. O., Chiou, R., Ha, V. L., Wallace, W. D., Chon, A. T., Hegab, A. E., Grogan, T., Elashoff, D. A., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.009 · Cited by 286
Tang, H., Xiao, G., Behrens, C., Schiller, J., Allen, J., Chow, C.-W., Suraokar, M., Corvalan, A., Mao, J., White, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2321 · Cited by 284
Niemira, M., Collin, F., Szalkowska, A., Bielska, A., Chwialkowska, K., Reszec, J., Niklinski, J., Kwasniewski, M., & Kretowski, A. (2019) · Cancers · doi:10.3390/cancers12010037 · Cited by 279
The molecular pathology of cancer
Harris, T. J. R., & McCormick, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 276
Diagnosis and Molecular Classification of Lung Cancer
Rodriguez-Canales, J., Parra-Cuentas, E., & Wistuba, I. I. (2016) · Cancer Treatment and Research · doi:10.1007/978-3-319-40389-2_2 · Cited by 273
Exhaled biomarkers in lung cancer
Horváth, I., Lázár, Z., Gyulai, N., Kollai, M., & Losonczy, G. (2009) · European Respiratory Journal · doi:10.1183/09031936.00142508 · Cited by 268
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
Hwang, I., Kim, J. W., Ylaya, K., Chung, E. J., Kitano, H., Perry, C., Hanaoka, J., Fukuoka, J., Chung, J.-Y., & Hewitt, S. M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02618-z · Cited by 253
HMGA2 functions as a competing endogenous RNA to promote lung cancer progression
Kumar, M. S., Armenteros-Monterroso, E., East, P., Chakravorty, P., Matthews, N., Winslow, M. M., & Downward, J. (2014) · Nature · doi:10.1038/nature12785 · Cited by 253
RetractedKMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243
Integrated Analysis of lncRNA–Mediated ceRNA Network in Lung Adenocarcinoma
Wu, X., Sui, Z., Zhang, H., Wang, Y., & Yu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554759 · Cited by 198
Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis
Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189
Zhang, Y., Sheng, J., Kang, S., Fang, W., Yan, Y., Hu, Z., Hong, S., Wu, X., Qin, T., Liang, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107161 · Cited by 175
Natural polyphenols in cancer therapy
Asensi, M., Ortega, A., Mena, S., Feddi, F., & Estrela, J. M. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.631268 · Cited by 174
Protein nanocages that penetrate airway mucus and tumor tissue
Huang, X., Chisholm, J., Zhuang, J., Xiao, Y., Duncan, G., Chen, X., Suk, J. S., & Hanes, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705407114 · Cited by 131
Becker, A., Crombag, L., Heideman, D. A. M., Thunnissen, F. B., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.046 · Cited by 117
Grossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.015 · Cited by 111
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer
Ma, L., Wen, Z.-S., Liu, Z., Hu, Z., Ma, J., Chen, X.-Q., Liu, Y.-Q., Pu, J.-X., Xiao, W.-L., Sun, H.-D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020159 · Cited by 96
Lockwood, W. W., Chari, R., Coe, B. P., Thu, K. L., Garnis, C., Malloff, C. A., Campbell, J., Williams, A. C., Hwang, D., Zhu, C.-Q., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000315 · Cited by 89
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1238 · Cited by 53
Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
Mehta, A., Dalle Vedove, E., Isert, L., & Merkel, O. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2665-9 · Cited by 53
Phosphorylation of FADD by the kinase CK1α promotes KRAS G12D -induced lung cancer
Bowman, B. M., Sebolt, K. A., Hoff, B. A., Boes, J. L., Daniels, D. L., Heist, K. A., Galbán, C. J., Patel, R. M., Zhang, J., Beer, D. G., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005607 · Cited by 48
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, H., Moore, J., Malonia, S. K., Li, Y., Ozata, D. M., Hough, S., Song, C.-Q., Smith, J. L., Fischer, A., Weng, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620861114 · Cited by 46
YEATS4 Is a Novel Oncogene Amplified in Non–Small Cell Lung Cancer That Regulates the p53 Pathway
Pikor, L. A., Lockwood, W. W., Thu, K. L., Vucic, E. A., Chari, R., Gazdar, A. F., Lam, S., & Lam, W. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1897 · Cited by 44
Structural basis of mutant-selectivity and drug-resistance related to CO-1686
Yan, X.-E., Zhu, S.-J., Liang, L., Zhao, P., Choi, H. G., & Yun, C.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.18588 · Cited by 43
Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1208 · Cited by 34
Pérez-Ramírez, C., Cañadas-Garre, M., Alnatsha, A., Villar, E., Delgado, J. R., Faus-Dáder, M. J., & Calleja-Hernández, M. Ÿ. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.002 · Cited by 33
Han, L., Zhang, X., Wang, Z., Zhang, X., Zhao, L., Fu, W., Liang, X., Zhang, Z., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665253 · Cited by 31
Zovko, A., Novak, M., Hååg, P., Kovalerchick, D., Holmlund, T., Färnegårdh, K., Ilan, M., Carmeli, S., Lewensohn, R., & Viktorsson, K. (2016) · Oncotarget · doi:10.18632/oncotarget.10361 · Cited by 28
Yuan, M., Xu, L.-F., Zhang, J., Kong, S.-Y., Wu, M., Lao, Y.-Z., Zhou, H., Zhang, L., & Xu, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00586 · Cited by 26
miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells
Tang, H., Lv, W., Sun, W., Bi, Q., & Hao, Y. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.4041 · Cited by 21
Tanaka, H., Sakagami, H., Kaneko, N., Konagai, S., Yamamoto, H., Matsuya, T., Yuri, M., Yamanaka, Y., Mori, M., Takeuchi, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0976 · Cited by 18
Murakami, H., Nokihara, H., Hayashi, H., Seto, T., Park, K., Azuma, K., Tsai, C., Yang, J. C., Nishio, M., Kim, S., et al. (2018) · Cancer Science · doi:10.1111/cas.13724 · Cited by 17
de Jong, C., Herder, G. J. M., & Deneer, V. H. M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13683 · Cited by 8
Metadata
- Authors
- Herbst, R. S., Heymach, J. V., & Lippman, S. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-09-25
- Volume
- 359
- Issue
- 13
- Pages
- 1367-1380
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2566863750
- Cited by
- 2,389
- References
- 130
- FWCI
- 79.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.